Curtis, Michael
Wilkinson, Anna L.
Dietze, Paul
Stewart, Ashleigh C.
Kinner, Stuart A.
Winter, Rebecca J.
Aitken, Campbell
Walker, Shelley J.
Cossar, Reece D.
Butler, Tony
Stoové, Mark
Funding for this research was provided by:
National Health and Medical Research Council (APP1168954)
Article History
Received: 11 June 2022
Accepted: 20 March 2023
First Online: 28 March 2023
Declarations
:
: Ethics approvals for the Prison and Transition Health Cohort Study were obtained from the Alfred Hospital Ethics Committee (79/12) DJCS (CF/14/10169) and AIHW Ethics Committee (EO2014/1/77). All study participants provided consent.
: All study participants provided consent.
: PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest. MS has received investigator-initiated funding from Gilead Sciences, AbbVie and Bristol Myers Squibb, and consultant fees from Gilead Sciences for activities unrelated to this work.